SK-N-SH Cell Line

SK-N-SH Cell Line

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">SK-N-SH Cell Line</th>
</tr>
<tr>
<td class="label">Organism</td>
<td>Homo sapiens (human)</td>
</tr>
<tr>
<td class="label">Age</td>
<td>4 years</td>
</tr>
<tr>
<td class="label">Gender</td>
<td>Female</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Neuroblastoma</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Metastatic site</td>
<td>Bone marrow</td>
</tr>
<tr>
<td class="label">Growth properties</td>
<td>Adherent</td>
</tr>
<tr>
<td class="label">Morphology</td>
<td>Epithelial (S-type) / Neuronal (N-type)</td>
</tr>
<tr>
<td class="label">Karyotype</td>
<td>Hyperdiploid human female (XX), modal chromosome number 47, trisomic for N7</td>
</tr>
<tr>
<td class="label">Biosafety Level</td>
<td>BSL 1</td>
</tr>
<tr>
<td class="label">Medium</td>
<td>Eagle's Minimum Essential Medium (EMEM) + 10% FBS</td>
</tr>
<tr>
<td class="label">Temperature</td>
<td>37°C</td>
</tr>
<tr>
<td class="label">Doubling time</td>
<td>~48 hours</td>
</tr>
<tr>
<td class="label">Cell Line</td>
<td>ATCC</td>
</tr>
<tr>
<td class="label">SH-SY5Y</td>
<td>CRL-2266</td>
</tr>
<tr>
<td class="label">SK-N-MC</td>
<td>HTB-10</td>
</tr>
<tr>
<td class="label">IMR-32</td>
<td>CCL-127</td>
</

SK-N-SH Cell Line

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">SK-N-SH Cell Line</th>
</tr>
<tr>
<td class="label">Organism</td>
<td>Homo sapiens (human)</td>
</tr>
<tr>
<td class="label">Age</td>
<td>4 years</td>
</tr>
<tr>
<td class="label">Gender</td>
<td>Female</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Neuroblastoma</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Metastatic site</td>
<td>Bone marrow</td>
</tr>
<tr>
<td class="label">Growth properties</td>
<td>Adherent</td>
</tr>
<tr>
<td class="label">Morphology</td>
<td>Epithelial (S-type) / Neuronal (N-type)</td>
</tr>
<tr>
<td class="label">Karyotype</td>
<td>Hyperdiploid human female (XX), modal chromosome number 47, trisomic for N7</td>
</tr>
<tr>
<td class="label">Biosafety Level</td>
<td>BSL 1</td>
</tr>
<tr>
<td class="label">Medium</td>
<td>Eagle's Minimum Essential Medium (EMEM) + 10% FBS</td>
</tr>
<tr>
<td class="label">Temperature</td>
<td>37°C</td>
</tr>
<tr>
<td class="label">Doubling time</td>
<td>~48 hours</td>
</tr>
<tr>
<td class="label">Cell Line</td>
<td>ATCC</td>
</tr>
<tr>
<td class="label">SH-SY5Y</td>
<td>CRL-2266</td>
</tr>
<tr>
<td class="label">SK-N-MC</td>
<td>HTB-10</td>
</tr>
<tr>
<td class="label">IMR-32</td>
<td>CCL-127</td>
</tr>
<tr>
<td class="label">M17</td>
<td>—</td>
</tr>
<tr>
<td class="label">LUHMES</td>
<td>—</td>
</tr>
<tr>
<td class="label">PC12</td>
<td>CRL-1721</td>
</tr>
</table>

Overview

SK-N-SH (ATCC HTB-11) is a human neuroblastoma cell line widely used in neurobiology and neurodegeneration research. Established from a bone marrow metastasis in a 4-year-old female patient in 1970, this cell line serves as a valuable in vitro model for studying neuronal differentiation, neurotoxicity, and therapeutic interventions for neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD)[@biedler1973][@ciccarone1989].

The cell line exhibits a unique bipotential nature, with cells capable of existing in either a neuronal (N-type) or substrate-adherent (S-type) morphology. This heterogeneity reflects the developmental plasticity of neural crest-derived cells and has made SK-N-SH a valuable model for studying cellular differentiation and lineage commitment[@ross1983].

Basic Characteristics

Origin and History

The SK-N-SH cell line was developed by J.L. Biedler and colleagues at the Memorial Sloan Kettering Cancer Center[@biedler1973]. The cell line was deposited by G. Trempe and L.J. Old and accessioned into the ATCC collection as HTB-11.

SK-N-SH differs from related neuroblastoma lines (such as SK-N-MC, ATCC HTB-10) in several key aspects:

• Longer population doubling time
• Higher levels of dopamine-beta-hydroxylase (DBH) expression
• Greater capacity for neuronal differentiation
• More pronounced catecholamine metabolism

Cellular and Molecular Characteristics

Morphological Variants

SK-N-SH cells exist in two main morphological forms:

N-type (neuronal) cells:

• Small, round cell bodies with short neurite-like extensions
• Higher expression of neuronal markers
• Capable of electrical excitability
• More relevant for neuronal studies

• Larger, flat cells with extensive cytoplasmic spread
• Strong adhesion to tissue culture substrate
• Less neuronal in character
• May represent a more proliferative state

Marker Expression

Key neuronal markers expressed in SK-N-SH include:

Cytoskeletal proteins:

• Neurofilament proteins (NF-L, NF-M, NF-H)
• MAP2 (Microtubule-associated protein 2)
• [Tau protein](/proteins/tau)

• Neuron-specific enolase (NSE)
• Tyrosine hydroxylase (TH) — rate-limiting enzyme in dopamine synthesis
• [Dopamine](/mechanisms/dopaminergic-signaling)beta-hydroxylase (DBH)
• Glutamate decarboxylase (GAD)
• Choline acetyltransferase (ChAT)

• Synaptophysin
• Synapsin I
• PSD-95

• TrkA (nerve growth factor receptor)
• TrkB (BDNF receptor)
• Dopamine transporter (DAT)
• NMDA and AMPA glutamate receptors[@cheng2002]

Neurotransmitter Systems

SK-N-SH cells possess functional neurotransmitter systems:

Dopaminergic properties:

• Express tyrosine hydroxylase (TH) and can synthesize L-DOPA
• Express dopamine-beta-hydroxylase (DBH) for conversion to norepinephrine
• Possess functional dopamine transporter (DAT)
• Capable of dopamine release upon depolarization[@cheng2002]

• Express glutamate decarboxylase (GAD)
• Synthesize and release GABA
• GABA-A receptor functional

• Express choline acetyltransferase (ChAT)
• Capable of [acetylcholine](/entities/acetylcholine) synthesis

Differentiation Protocols

SK-N-SH cells can be differentiated toward a more mature neuronal phenotype using various agents. Differentiated cells show enhanced neuronal characteristics and are more relevant for studying age-related neurodegeneration[@phlman1991].

Retinoic Acid Differentiation

All-trans retinoic acid (RA) is the most commonly used differentiation agent:

Protocol:

• RA concentration: 10 μM
• Duration: 5-7 days
• Medium change: Every 2 days

• Extension of long, branching neurites
• Increased expression of neuronal markers (MAP2, neurofilament)
• Enhanced neurotransmitter synthesis
• Reduced proliferation rate
• Electrophysiological maturation[@phlman1991][@encinas2000]

BDNF-Induced Differentiation

Brain-derived neurotrophic factor promotes neuronal differentiation and survival:

Protocol:

• BDNF concentration: 50-100 ng/mL
• Duration: 3-5 days
• Often combined with RA pretreatment

• Enhanced neurite outgrowth
• Increased neuronal marker expression
• Improved neuronal survival
• Synapse formation[@encinas2000]

Sequential Differentiation (RA + BDNF)

A two-stage protocol produces more mature [neurons](/entities/neurons):

Stage 1 (Days 1-5):

• 10 μM all-trans retinoic acid
• Promotes initial neuronal differentiation

• Remove RA, add BDNF (50 ng/mL)
• Promotes maturation and survival

cAMP Differentiation

Elevated intracellular cAMP drives neuronal differentiation:

Protocol:

• Forskolin (10 μM) + IBMX (50 μM), or
• Dibutyryl-cAMP (1 mM)
• Duration: 2-5 days

• Morphological changes toward neuronal phenotype
• Increased neuronal marker expression
• Enhanced neurotransmitter release[@scheibe1986]

Phorbol Ester Differentiation

Phorbol 12-myristate 13-acetate (PMA) activates PKC:

Protocol:

• PMA concentration: 10-50 nM
• Duration: 3-5 days

• Neurite outgrowth
• Expression of neuronal markers
• Note: PKC activation may have complex effects on signaling pathways

Applications in Alzheimer's Disease Research

SK-N-SH cells have been extensively used as an in vitro model for studying Alzheimer's disease mechanisms[@yao2011]:

Amyloid-beta Toxicity Studies

• [Aβ](/proteins/amyloid-beta)-induced oxidative stress: SK-N-SH cells exposed to Aβ peptides show increased [ROS](/entities/reactive-oxygen-species) production, lipid peroxidation, and mitochondrial dysfunction[@yao2011]
• Neuroinflammation: Treatment with Aβ increases M-CSF (macrophage colony-stimulating factor) and other inflammatory mediators
• Synaptic dysfunction: Aβ exposure affects synaptic marker expression and function
• [Autophagy](/entities/autophagy) studies: Aβ triggers autophagy dysregulation in these cells

Tau Pathology Models

• Hyperphosphorylated tau expression: Transfection with mutant tau constructs
• Tau aggregation: Studies on tau oligomerization and fibrillization
• Tau-mediated toxicity: Investigation of tau-induced neuronal death pathways
• Therapeutic screening: Testing anti-tau compounds for efficacy[@chen2013]

Neurotrophin Signaling

SK-N-SH express Trk receptors and are used to study:

• BDNF/TrkB signaling in neuronal survival and plasticity
• APP processing and [amyloid precursor protein](/entities/app-protein) metabolism
• Effects of AD-associated mutations (APP, [PSEN1](/entities/psen1), PSEN2) on cellular function
• [NMDA receptor](/entities/nmda-receptor) function and excitotoxicity

Drug Screening Platforms

Pharmaceutical and academic researchers use SK-N-SH for:

• Anti-amyloid compounds: Screening for Aβ-lowering or Aβ-protective agents
• Neuroprotective agents: Compounds that protect against Aβ toxicity
• Antioxidants: Testing compounds that counteract oxidative stress
• Anti-tau therapies: Small molecules and antibodies targeting tau pathology
• Repurposing screens: FDA-approved drugs for potential AD treatment[@chen2013]

Limitations in AD Research

• Tumor-derived cells may not fully recapitulate primary neurons
• Lack of tau pathology in vivo context
• Cannot model complex glia-neuron interactions
• Missing [blood-brain barrier](/entities/blood-brain-barrier)

Applications in Parkinson's Disease Research

SK-N-SH cells serve as a valuable model for PD research, particularly for dopaminergic neuron biology[@xie2010]:

Dopaminergic Differentiation

SK-N-SH can be differentiated toward a dopaminergic phenotype:

• Expression of TH, DAT, and AADC
• Dopamine synthesis and release upon stimulation
• Metabolic studies of dopaminergic neurons
• Development studies of midbrain dopaminergic lineages

Alpha-Synuclein Studies

The cell line is used to model Lewy body pathology:

• Wild-type SNCA overexpression: Aggregation and toxicity studies
• Mutant [alpha-synuclein](/proteins/alpha-synuclein): A30P, E46K, A53T mutations
• Oligomerization mechanisms: How wild-type and mutant proteins form oligomers
• Transmission studies: Cell-to-cell propagation of alpha-synuclein[@da2022]
• Therapeutic screening: Compounds that prevent aggregation or enhance clearance

Neurotoxin Models

PD-relevant neurotoxins are used to model dopaminergic degeneration:

MPP+ (1-methyl-4-phenylpyridinium):

• Active metabolite of MPTP
• Inhibits mitochondrial complex I
• Induces selective dopaminergic degeneration
• Used to study mitochondrial dysfunction in PD[@xie2010]

• Oxidative stress inducer
• Selective for catecholaminergic neurons
• Causes rapid dopaminergic degeneration
• Used for neuroprotective compound screening

• Natural mitochondrial complex I inhibitor
• Produces PD-like pathology in animals
• Used in vitro to model mitochondrial dysfunction

LRRK2 Research

SK-N-SH expressing mutant [LRRK2](/entities/lrrk2) are used to study:

• LRRK2 kinase activity and substrate phosphorylation
• Pathogenic mutations: G2019S, R1441C/G, I2020T
• LRRK2 inhibitors: Kinase inhibitors for therapeutic development
• Alpha-synuclein interaction: How LRRK2 affects synucleinopathy[@cookson2010]

Limitations in PD Research

• Not true midbrain dopaminergic neurons
• Lacks the substantia nigra microenvironment
• Cannot fully model chronic progressive neurodegeneration
• Missing neuromelanin synthesis

Genetic Manipulation

SK-N-SH cells are readily amenable to genetic manipulation:

Transfection

• Plasmid transfection: Lipofection, calcium phosphate, electroporation
• Stable cell lines: G418, puromycin, hygromycin selection
• Transient expression: For rapid functional studies

Viral Vectors

• Lentivirus: For stable integration and difficult-to-transfect genes
• Adenovirus: High-efficiency transient expression
• AAV: For long-term gene expression

CRISPR/Cas9 Gene Editing

• Knockout: Target genes of interest
• Knockin: Insert disease-associated mutations
• CRISPRi/a: Transcriptional activation or repression

RNAi Technologies

• siRNA: Transient knockdown
• shRNA: Stable knockdown via lentiviral vectors
• CRISPRi: Catalytically dead Cas9 for gene repression

Related Cell Lines

Limitations and Considerations

Despite these limitations, SK-N-SH remains a valuable and widely-used model system for initial studies and drug screening before validation in more complex systems.

See Also

• [SH-SY5Y](/cell-types/sh-sy5y)
• [IMR-32](/cell-types/imr-32)
• [Alzheimer's Disease Cell Models](/diseases/alzheimers-disease)
• [Parkinson's Disease Cell Models](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)